Oncolytic virotherapy in upper gastrointestinal tract cancers

Abstract: Upper gastrointestinal tract malignancies are among the most challenging cancers with regard to response to treatment and prognosis. Cancers of the esophagus, stomach, pancreas, liver, and biliary tree have dismal 5-year survival, and very modest improvements in this rate have been made in recent times. Oncolytic viruses are being developed to address these malignancies, with a focus on high safety profiles and low off-target toxicities. Each viral platform has evolved to enhance oncolytic potency and the clinical response to either single-agent viral therapy or combined viral treatment with radiotherapy and chemotherapy. A panel of genomic alterations, chimeric proteins, and pseudotyped capsids are the breakthroughs for vector success. This article revisits developments for each viral platform to each tumor type, in an attempt to achieve maximum tumor selectivity. From the bench to clinical trials, the scope of this review is to highlight the beginnings of translational oncolytic virotherapy research in upper gastrointestinal tract malignancies and provide a bioengineering perspective of the most promising platforms.

Keywords: oncolytic viruses, hepatopancreatobiliary, gastric cancer, pancreatic cancer, liver cancer, biliary cancer

Introduction

Gastrointestinal cancers are considered a significant challenge in public health worldwide. In the US, pancreatic adenocarcinoma and hepatocellular carcinoma (HCC) appear among the ten most deadly cancers each year.1 New drugs to combat those cancers are being developed, and arrays of oncolytic viral vectors are progressing into clinical studies. Oncolytic viral therapy in upper gastrointestinal tract (UGT) malignancies represents a promising therapeutic platform. Virotherapy can allow for combination with immunotherapies or cytotoxic chemotherapies or used as a standalone platform for gene therapy in the context of cancer ultimately being a genetic disease.

Genomic profiling of UGT malignancies has yielded compendia of mutations, regions of loss of heterogeneity, gene fusions/translocations, and copy-number alterations responsible for pathogenesis, disease recurrence, and drug resistance. This review will cover the implementation of oncolytic virotherapy (OV) in esophageal, gastric, pancreatic, liver, and biliary cancers from a bedside-to-bench perspective.

Upper gastrointestinal tract malignancies

One of the recent forays of OV in the clinic was in patients with head and neck cancers. China approved the first virus (H101) for nasopharyngeal cancers in November.
H101 is a recombinant adenovirus (Ad) very similar to ONYX15 that had been studied in the US, but efforts were unable to be sustained beyond initial clinical studies. The approval of H101 provided a much-needed boost to the field for ongoing investigation. More recently, a herpes simplex virus (HSV)-based vector (T-Vec) garnered US Food and Drug Administration approval in 2015 for the treatment of patients with advanced melanoma.

Pursuant to these efforts, sustained interest in the field of OV has been fostered, aided by more comprehensive understanding of the genetic underpinnings of cancers, as well as improved understanding and success of cancer immunotherapies as a mainstay of cancer treatment and a growing appreciation of the potential for evaluating OV, combined with these existing therapeutic modalities. Given the difficult prognosis of patients with advanced UGT malignancies, OV represents a promising platform for the development of novel therapeutics.

Esophageal cancer

Esophageal cancer has an incidence of nearly 17,000 people per year in the US, and the 5-year survival is less than 19%. Early metastasis and diagnosis at advanced clinical stage are responsible for the poor prognosis and high mortality of the disease. One of the early attempts at use of OV in esophageal cancer used herpes simplex virus type 1 (HSV1) as the viral platform. The approach took advantage of the mucosal tropism of the strain equipped with GFP for visualization/monitoring. The cytotoxic effect of the virus was evaluated, first in vitro using BE3 cell lines, and thereafter in vivo with an intraperitoneal tumor model (Table 1). The study concluded that the viral platform could be used to mark esophageal cancer cells from a diagnostic approach at the time of endoscopy.

BE3 has served as a cell-line model for esophageal adenocarcinoma and Barrett’s esophagus. Interestingly, that viral platform was derived from the HSV1 strain NV1023 that was used herpes simplex virus type 1 (HSV1) as the viral platform. The approach took advantage of the mucosal tropism of the strain equipped with GFP for visualization/monitoring. The cytotoxic effect of the virus was evaluated, first in vitro using BE3 cell lines, and thereafter in vivo with an intraperitoneal tumor model (Table 1). The study concluded that the viral platform could be used to mark esophageal cancer cells from a diagnostic approach at the time of endoscopy.

Later, a modified Ad was developed to establish a platform that could induce cell-cycle arrest. Increased cytotoxicity was observed against p53-mutant esophageal cancer cells. Additionally, greater oncolytic effect with reduced NFkB and enhanced apoptosis was noted. Correspondingly, a newly modified herpes simplex virus type 2 (HSV2) was developed with oncolytic effect on esophageal cancer cell lines. The N-terminal of the ICP10 gene of HSV2 was modified by deleting a protein-kinase domain. This deletion increased the bystander-killing effect of the virus, enhancing apoptosis. The mutant virus was designated FusOnH2.

A study evaluating resistant tumor cells with properties similar to the cancer stem cells was conducted using an Ad carrying an apoptotic gene, TRAIL, which would preferentially induce apoptosis in these resistant cells. Further, another group evaluated the combinatorial effects of chemotherapy and oncolytic therapy with an Ad. They used four drugs and a modified Ad, with deletion of the 55 kDa-encoding E1B region and a part of the E3 region, generating the vector Ad-delE1B55. The four drugs tested were fluorouracil (5FU), etoposide (VP16), mitomycin C, and cisplatin (CDDP). 5FU enhanced the cell cycle at the S phase and then induced G2–M phase entry, whereas CDDP induced G1 phase arrest. Ad-delE1B55 also induced the S phase and G2/M phase such that G1 phase arrest by CDDP was inhibitory to Ad-mediated cell-cycle progression and as a result was unfavorable to Ad-mediated toxicities. On the other hand, the Ad-induced S phase and G2/M phase impeded CDDP-mediated cytotoxicity, and thus the cytotoxicity between the Ad and CDDP promoted cross-resistance.

A third-generation HSV1 improved the oncolytic effect by incorporating a gene of fusogenic proteins with transgenes for gibbon-ape leukemia virus (GALV) encoded into the viral genome. Furthermore, another group built upon their work with Ad-TRAIL-E1 toward the development of the vector Ad-hTERT-E1 (Telomelysin OBP301), under the control of hTERT. This vector has progressed to clinical trials for esophageal cancer.

In the same year, another group evaluated the adenoviral vector H101 in esophageal carcinoma. Following this, an enhanced antitumor effect in esophageal cancer cell lines was observed with H101 through the overexpression of cosackie and adenovirus receptor (CAR) using trichostatin A. Enhanced oncolytic activity was achieved through MAPK–ERK pathway induction of viral proliferation. Recently, another study has demonstrated that trichostatin A enhances the spread and replication of adenoviral vectors in several infection-resistant cancers.

A chimeric vector, Ad-hTERTp-E1A-HN, which uses the same adenoviral backbone as H101 coupled with the hemagglutinin–neuraminidase gene from Newcastle disease virus (NDV), has been evaluated in preclinical esophageal cancer models. Hemagglutinin–neuraminidase is a 75-kDa membrane glycoprotein that has the potential to boost innate immunity. Its neuraminidase activity allows for hydrolysis of sialic acid on the receptors of host cells. It can also induce
IFNα and TRAIL production in peripheral blood mononuclear cells, leading to enhancement of apoptotic pathways. The study of esophageal cancer observed cytotoxicity by an increase in reactive oxygen species. In vivo evaluation demonstrated complete responses and prolonged survival with intratumoral injection of the vector.18

A number of vectors have been entering clinical trials following these preclinical evaluations. A Phase I clinical trial for Telomelysin OBP301 is awaiting initiation (ClinicalTrials.gov NCT03213054). These efforts mark the transition of OV from bench to bedside in esophageal cancer. Future directions entail safety evaluation and optimal dosing of vectors, followed by combinatorial assessment with existing therapies, particularly immunotherapies.

**Gastric cancer**

Gastric cancer is the fifth most common cancer in the world. It has a 5-year overall survival (OS) rate of 30.6%. Surgery is the only curative treatment, but less than a quarter of cases are eligible.20 OV for gastric cancer was initially tested in vivo in mouse models of peritoneal carcinomatosis. Initially, two oncolytic HSV vectors (G207 and NV1020) were tested. Locoregional therapy was found to be efficacious. However, systemic delivery through intravenous administration failed to diminish tumor burden.21 In another study, apoptosis inhibitors were used in conjunction with viral vectors. It was found that N-acetyl cysteine improved killing of neighboring uninfected cells using the NV1066 platform.22

Later, the first tumor-specific promoters were tested for conditionally replicating Ads (CR-Ads) in gastric cancer.23 midkine and cyclooxygenases (Cox2M and Cox2L) promoters demonstrated high transcriptional activity in gastric cancer cells, and the Cox2CR-Ad showed a potent oncolytic effect. A fiber-modified vector, Ad5/3, also yielded robust infectivity in this study.23 With its serotype 3 knob, Ad5 allows the vector to bind to a receptor different from CAR. Another study used

### Table 1 Oncolytic viral platforms for esophageal cancer

<table>
<thead>
<tr>
<th>Year</th>
<th>Vector</th>
<th>Final viral construct or viral-based strain</th>
<th>Vector modifications</th>
<th>Details</th>
<th>Reference(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2003</td>
<td>HSV1</td>
<td>NV1066</td>
<td>Vector under CMV promoter Expressing eGFP</td>
<td>Could be used as a marker in endoscopy, as well as laparoscopically for carcinomatosis</td>
<td>6, 8</td>
</tr>
<tr>
<td>2004</td>
<td>Ad</td>
<td>AxE1AdB was used to create AxdAdB3</td>
<td>Deleted 55 kDa-encoding E1B region E1A gene designed to abolish binding retinoblastoma protein</td>
<td>Increased cytotoxicity against p53-mutant esophageal cancer cell lines, higher in vivo oncolytic effect, despite similar replication efficiency in vitro</td>
<td>9</td>
</tr>
<tr>
<td>2007</td>
<td>HSV2</td>
<td>Fus-OnH2</td>
<td>PK domain deleted in the ICP10 gene</td>
<td>Effective in tumors with resistance to apoptosis</td>
<td>10</td>
</tr>
<tr>
<td>2008</td>
<td>Ad</td>
<td>Ad/TRAIL-E1</td>
<td>Vectors under hTERT controlling E1A and TRAIL</td>
<td>Preferentially targeting radioresistant cells with stem-cell-like properties</td>
<td>11</td>
</tr>
<tr>
<td>2010</td>
<td>HSV1</td>
<td>OncovexGALV/CD</td>
<td>Double deletion of the γ134.5 gene attenuates the virus to make it less neurotropic Deletion of ICP47 increases antigen presentation within infected tumor cells Vector encoding a fusogenic protein with transgene-encoding GALV</td>
<td>Efficient infection and oncolysis in gastroesophageal cancer cells with viral platform expressing large syncytia</td>
<td>13</td>
</tr>
<tr>
<td>2010</td>
<td>Ad</td>
<td>Ad-delE1B55</td>
<td>Vectors under CMV promoter Deleted 55 kDa-encoding E1B region and a part of the E3 region</td>
<td>Combinatory antitumor effect depends on the chemotherapy agent</td>
<td>12</td>
</tr>
<tr>
<td>2011</td>
<td>Ad</td>
<td>Telomelysin OBP301</td>
<td>hTERT promoter Deleted 55 kDa-encoding E1B region</td>
<td>Intratumoral injection followed by radiation had a substantial antitumor effect</td>
<td>14</td>
</tr>
<tr>
<td>2014</td>
<td>Ad</td>
<td>Ad-hTERT-pE1A-HN</td>
<td>hTERT promoter Deleted 55 kDa-encoding E1B region Expressing HN from NDV</td>
<td>Suppression of tumor volume using both modes of delivery (IT and IV)</td>
<td>18</td>
</tr>
<tr>
<td>2015</td>
<td>Ad</td>
<td>Ad SG502-TNF</td>
<td>SG502-TNF containing luciferase-reporter gene</td>
<td>Complete response to vector IT injection SG502-TNF targeted tumor cells specifically with stable expression of TNF</td>
<td>19</td>
</tr>
</tbody>
</table>

**Abbreviations:** HSV1, herpes simplex virus type 1; HSV2, herpes simplex virus type 2; CMV, cytomegalovirus; Ad, adenovirus; PK, protein kinase; GALV, gibbon ape leukemia virus; HN, hemagglutinin–neuraminidase; IT, intratumoral; IV, intravenous; NDV, Newcastle disease virus; TNF, tumor necrosis factor.
### Table 2 Oncolytic viral platforms for gastric cancer

<table>
<thead>
<tr>
<th>Year</th>
<th>Vector</th>
<th>Final viral construct or viral-based strain</th>
<th>Vector modifications</th>
<th>Details</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>2002</td>
<td>HSV1</td>
<td>G207, NV1020</td>
<td>G207: deletion of both copies of γ34.5 genes and inactivation of ICP6 gene; NV1020: deletion of one copy of γ34.5 and intact ICP6 gene</td>
<td>In vitro studies were similar, with NV1020 having better results at lower viral concentrations</td>
<td>21</td>
</tr>
<tr>
<td>2004</td>
<td>HSV1</td>
<td>NV1066</td>
<td>Early gene copies of ICP0 and ICP4 and the γ34.5 gene</td>
<td>Exposure to NAC promoted killing</td>
<td>22</td>
</tr>
<tr>
<td>2006</td>
<td>Ad</td>
<td>AdCEAp/Rep</td>
<td>CEA promoter (conditionally replicating)</td>
<td>Cytotoxicity against CEA-producing cells was dose-dependent and different from CEA-negative cells</td>
<td>25</td>
</tr>
<tr>
<td>2009</td>
<td>Ad</td>
<td>AdE2F-p16</td>
<td>p16-expression cassette was inserted upstream of the E2F promoter; Data were normalized with those of CMV promoter</td>
<td>Tumor-inhibition rate in xenografts was 59%</td>
<td>26</td>
</tr>
<tr>
<td>2009</td>
<td>Evi</td>
<td>Farouk virus</td>
<td>No alterations were made</td>
<td>Specific targeting of α2β1</td>
<td>27</td>
</tr>
<tr>
<td>2009</td>
<td>Ad</td>
<td>AdS/35</td>
<td>Fiber shaft and knob from Ad35 into Ad5 E1B deleted SG235-TRAIL</td>
<td>More efficient cell entry</td>
<td>45</td>
</tr>
<tr>
<td>2010</td>
<td>NDV</td>
<td>NDV(F3aa)-GFP</td>
<td>Cleavage site of the F protein was modified with three amino-acid changes, making it more fusogenic; Expressing GFP</td>
<td>Treated mice exhibited a significant reduction in tumor development and prolonged survival</td>
<td>28</td>
</tr>
<tr>
<td>2010</td>
<td>Reovirus</td>
<td>ReoT3D</td>
<td>No alterations were made</td>
<td>Diminished ascites volume and tumor burden</td>
<td>30</td>
</tr>
<tr>
<td>2012</td>
<td>HSV1</td>
<td>HSV (T-TSP1)</td>
<td>Expressing TSP1</td>
<td>Arming the virus attenuated its replication in some cell lines, but cytotoxicity was not affected; Enhanced inhibition of angiogenesis was observed</td>
<td>31</td>
</tr>
<tr>
<td>2012</td>
<td>Ad</td>
<td>Ad-hTERT-E1A-apoptin</td>
<td>Ad under hTERT promoter with E1A and apoptin</td>
<td>Ad-hTERT-E1A-apoptin resulted in complete response to treatment</td>
<td>32</td>
</tr>
<tr>
<td>2013</td>
<td>Ad</td>
<td>Telomelysin OBP301</td>
<td>hTERT promoter; Deleted 55 kDa-encoding E1B region</td>
<td>OBP-301 induced cell-cycle mobilization from G0–G1 to S/G2/M phases and subsequent cell death in quiescent CD133+ cancer stem-like cells by mobilizing cell-cycle-related proteins</td>
<td>33</td>
</tr>
<tr>
<td>2013</td>
<td>Ad</td>
<td>E1B55KD (AddI1520)</td>
<td>Deleted 55 kDa-encoding E1B region; Expressing endostatin</td>
<td>Selective replication and expression of endostatin in gastric cancer cells achieved synergistic effect</td>
<td>37</td>
</tr>
<tr>
<td>2013</td>
<td>Ad</td>
<td>AdSurp-Hsp70</td>
<td>Under survivin promoter; Expressing chaperone Hsp-70</td>
<td>Selective replication in surviving positive tumor cells</td>
<td>38</td>
</tr>
<tr>
<td>2014</td>
<td>Vaccinia</td>
<td>GLVI h153</td>
<td>Expressing Ruc-GFP fusion protein; Encoding rTFR, hNIS; Encoding thymidine kinase and hemagglutinin</td>
<td>Tumor regression over a 4-week period, with one animal with total regression</td>
<td>39</td>
</tr>
<tr>
<td>2015</td>
<td>NDV</td>
<td>La Sota strain NDV-RL-RVG</td>
<td>Expressing the rabies virus glycoprotein (rL-RVG)</td>
<td>Induced significant autophagy</td>
<td>40</td>
</tr>
<tr>
<td>2017</td>
<td>Ad</td>
<td>Ad/TRAIL-E1</td>
<td>TRAIL gene expression</td>
<td>Vector delivery through peritoneal injection was effective</td>
<td>42</td>
</tr>
<tr>
<td>2017</td>
<td>NDV</td>
<td>NDV-D90</td>
<td>Wild-type NDV isolated in China; no alterations were made</td>
<td>Reduced gastric cancer growth by inducing apoptosis and impairing gastric cancer vasculatization</td>
<td>43</td>
</tr>
</tbody>
</table>

**Abbreviations:** HSV, herpes simplex virus; HSV1, herpes simplex virus type 1; NAC, N-acetylcysteine; CMV, cytomegalovirus; Ad, adenovirus; CEA, carcinoembryonic antigen; EV, echovirus; NDV, Newcastle disease virus; Ruc, Renilla Aequorea luciferase; rTFR, reverse-inserted human transferrin receptor; hNIS, human sodium–iodide symporter.
this Ad5/3 capsid in an Ad5LucRGD vector. Incorporation of peptides Arg–Gly–Asp (RGD) in the fiber knob allowed the virus to utilize αβ2-class integrins for binding and internalization. These integrins are highly expressed in gastric cancers. The vector Ad5LucRGD also had polylsine motifs – pK7 and pK21 – that bound to heparan sulfates, which are overexpressed in gastric cancers. The receptor for Ad3 is believed to be CD46, which is also highly expressed in advanced gastric cancers. From this perspective, the chimeric capsid considerably improved viral infectivity.

In another study, a CEA promoter was introduced into an adenoviral vector to study conditional vector replication in CEA-expressing gastric carcinoma cells, paving the path for a CEA-promoter-driven CRAd in gastric cancers. Further, a viral platform targeting the cyclin D–CDK–p16–Rb–E2F pathway was created based on an Ad by inserting a p16-expression cassette upstream of the E2F promoter, thereby controlling E1A with the E2F promoter. This AdE2F-p16 replicated preferentially in tumor cells with the desired specificity, while sparing normal cells. Luciferase assays demonstrated that the promoter conferred vector selectivity in cancer cells compared to normal cells (Table 2). In a contemporaneous evaluation, echovirus 1 was evaluated for peritoneal dissemination in gastric cancer models by vector dissemination through the use of αβ1 integrins.

A subsequent study evaluated NDV as an oncolytic in gastric cancer. A bioengineering modification improved its fusogenic proteins by deleting three amino acids through reverse genetics. The new virus, NDVF3aa, was able to reduce the tumor burden in animal models of gastric cancer. Reovirus has also been studied in gastric cancer. It has a double-stranded RNA genome, and its oncolytic action depends on the presence of activated Ras-signaling pathways. This activation could be via direct Ras mutations, such as K-Ras or N-Ras, or downstream of other pathway activators, such as EGFR, Her2 (Neu/ErbB2), or SOS. These attributes make reovirus a desired OV candidate for targeting cancers that have Ras activity. In 2010, a study evaluating reovirus in Ras-activated gastric cancer models showed encouraging efficacy.

Gene therapy-based approaches to modulate the tumor microenvironment have also been pursued using viral vectors in gastric cancer. An HSV armed with thrombospondin 1 was evaluated in gastric cancer. Another study used apoptin to induce apoptosis specifically in tumor cells. Apoptin is a p53-independent, Bcl2-insensitive apoptotic protein that can induce programmed cell death only in cancer cells. An Ad under the hTERT promoter was utilized to carry the apoptin gene (Ad-hTERT-E1A-apoptin). In vitro and in vivo evaluations yielded promising efficacy, including a number of complete tumor regressions. The apoptin gene is derived from the chicken anemia virus, and it does not need a functional p53 pathway nor is it hindered by Bcl2 blockage of apoptosis.

Furthermore, another group evaluated the Ad OBP301 to target quiescent stem-like cells. These types of cells are largely resistant to conventional cytotoxic therapies as long as they are in a dormant phase. Mobilizing these quiescent cells into the cell cycle can reenable a response to treatment. This study demonstrated that cell-cycle mobilization and S/G2/M phase trapping could be induced by adenoviral infection. This was felt to be a significant accomplishment in solid-tumor OV, given that mobilization of quiescent cells into the cell cycle had only been previously achieved in leukemia.

Another study described a viral gene-therapy approach to create an Ad with endostatin. Endostatin is a 20 kDa C-terminal fragment of collagen XVIII known to be a potent inhibitor of angiogenesis. Synergistic effects of oncolysis and endostatin expression were achieved allowing for enhancement of virotherapy efficacy. In the same realm, another study evaluated an adenoviral platform with a survivin promoter and a chaperone gene – HSP70. The resultant vector (AdSurp-Hsp70) replicated selectively in survivin-positive gastric cancer cells and inhibited tumor growth in both immunodeficient and immunocompetent mice.

Conversely, a vaccinia virus with visible markers has been used for deep-tissue imaging in gastric cancer. The markers used were GFP and human NIS, which can be readily imaged with 99mTc scintigraphy and 124I positron-emission tomography. These types of approaches allow for noninvasive vector monitoring. Recently, a number of studies have evaluated chimeric vectors. An example of such a vector is the NDV La Sota strain expressing the rabies virus glycoprotein. This chimeric vector was found to have increased oncolytic efficacy in gastric cancer cell lines.

Besides vector development, delivery strategies have also been shown to have an impact on antitumor efficacy. An intraperitoneally delivered adenoviral vector exhibited efficacy in diminishing peritoneal carcinomatosis in a gastric cancer model. There has been considerable interest in evaluating wild-type virus strains known to have oncolytic properties. A wild-type NDV strain isolated in China named NDVD90 has shown promising preclinical efficacy in gastric cancer, selectively killing gastric cancer cells with no appreciable effect on normal cells. Vaccinia virus vectors have also garnered interest toward evaluation in gastric cancer. A clinical study evaluating a vaccinia viral oncolytic vector (GL-ONC1) was completed in Germany in gastric cancer.
patients with peritoneal carcinomatosis (ClinicalTrials.gov NCT01443260). Recently, synergistic cytotoxicity has been reported with concomitant OV and chemotherapy.45

**Pancreatic cancer**

Pancreatic cancer is one of the most challenging malignancies, with a 5-year OS of only 8.2%. Unfortunately, this rate has not changed over the last 20 years, despite some recent modest advances in systemic therapy with FOLFIRINOX and gemcitabine–nab-paclitaxel. As such, novel therapeutic approaches are in imminent need and oncolytic viruses represent a promising treatment approach in this regard. A number of clinical studies evaluating oncolytic viruses are ongoing (Table 3). Translational research is the main focus of these vectors being evaluated in pancreatic cancer.

Initially, such vectors as ONYX015 (Ad with E1B 55 kDa deletion) developed to treat other malignancies were evaluated in pancreatic tumor cancer cells. Findings were similar to other tumors, with the vector replicating in TP53-deficient cells.47 Since then, the field has quickly evolved to address specific challenges related to pancreatic tumors. From this perspective, research efforts have focused on overcoming 5FU resistance and using a gene-therapy approach: this effort has yielded the Ad AxE1AdB-UPRT. This Ad

<table>
<thead>
<tr>
<th>Table 3 Current clinical trials using oncolytic viruses for pancreatic cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Vector</strong></td>
</tr>
<tr>
<td>Ad</td>
</tr>
<tr>
<td>HSV1</td>
</tr>
<tr>
<td>Ad</td>
</tr>
<tr>
<td>Ad</td>
</tr>
<tr>
<td>Reovirus</td>
</tr>
<tr>
<td>Ad</td>
</tr>
<tr>
<td>Ad</td>
</tr>
<tr>
<td>PV</td>
</tr>
</tbody>
</table>

**Abbreviations:** Ad, adenovirus; IT, intratumoral; HSV, herpes simplex virus; HSV1, herpes simplex virus type 1; FU, fluorouracil.
vector is capable of expressing UPRT, which can overcome 5FU resistance.47 Given that host antiviral immunity can be an impediment to efficacy, evaluation was undertaken in immunocompetent models. Other studies have utilized immunosuppression with cyclophosphamide accompanying vector delivery in immunocompetent models, with encouraging results.48

In 2007, an Ad carrying suicide genes was successfully tested in preclinical models of pancreatic cancer. Ad5-γCD/mutTKSR39rep-ADP is an Ad5 vector carrying Ad cytosine deaminase and HSV thymidine kinase (TKS39). This vector augmented the effectiveness of pancreatic radiotherapy without resulting in excessive toxicity.49 Pursuant to this, other adenoviral vectors carrying TK genes in combination with ganciclovir were tested using an intraductal delivery approach, resulting in improved survival in vivo.50

The La Sota strain of NDV has been tested in pancreatic cancer models, with favorable efficacy. Pancreatic tumor-cell lines were 700 times more sensitive to cytotoxicity from the NDV La Sota strain in vivo pancreatic cancer models than normal pancreatic cells.51 Likewise, reovirus has been evaluated in pancreatic cancer. Given that it replicates only in cells that express an active Ras pathway and the nearly ubiquitous nature of Ras activation in pancreatic cancer, this virus became particularly interesting in this disease.52 In one study evaluating reovirus in pancreatic cancer, the vector proliferated to yield a considerable amount of viral particles and ubiquitinated proteins in the endoplasmic reticulum, causing apoptosis mediated by endoplasmic reticulum stress in vitro and in vivo.53

Human and avian influenza A viruses (IAVs) have also been evaluated in pancreatic cancer models.53 The appeal of these platforms was based on the natural tropism of IAV for pancreatic cells. The study confirmed the expression of α2,3-linked and α2,6-linked sialoglycans receptors, respectively, for avian and human IAV in pancreatic ductal adenocarcinoma (PDAC) cell lines. Correspondingly, IAVs did not infect normal pancreatic cells. Tropism and selectivity were observed, with promising antitumor efficacy both in vitro and in vivo.53

Tumor selectivity was a critical impetus for a study in pancreatic cancer that involved targeting MMP with an Ad bioengineered with a TAT-like peptide and linked to a blocking domain by an MMP-cleavable sequence and achieving MMP-dependent transduction. This viral platform, AdTAT-MMP, was shown to reduce local and distant metastases, with no significant toxicity in in vivo pancreatic cancer models.54

From the perspective of tumor selectivity, one research group identified a pancreatic cancer-targeting ligand (SYENFSA) that would boost the specificity of an Ad under a survivin promoter, achieving higher transduction efficiency. Ad Sur-SYE resulted in potent oncolysis in PDAC55 and superior efficiency when compared to the non-targeting virus AdSur for neuroendocrine pancreatic tumors when administrated intratumorally.56

In 2015, the oncolytic Ad VCN01 was also tested in vitro and in vivo for PDAC. VCN01 is characterized by the expression of hyaluronidase and the RGD shaft-retargeting ligand. As such, VCN01 employs a strategy whereby the tumor microenvironment can be modulated using a viral vector. Encouraging safety and efficacy have been noted with VCN01 in preclinical studies, paving its way toward clinical development.57

Second-generation HSV1 vectors have been evaluated in pancreatic cancer. Using recombinant HSV1, a novel viral platform was created with ICP6-defective expression and HSV1 γ134.5 gene expression, regulated by the cellular B-Myb promoter and giving rise to the viral vector Myb34.5.58 Tumor progression was inhibited with intratumoral injection of this virus alone, and tumor regression was achieved when virotherapy was combined with standard chemotherapeutic agents. In light of the promising preclinical data generated in these and other evaluations, a number of oncolytic vectors have progressed into clinical studies (Table 3).

**Liver and biliary cancers**

Liver and intrahepatic bile duct cancer affect around 40,000 people per year in the US, with nearly 29,000 deaths each year and a dismal 5-year OS of only 17.6%.59 Toxicity to neighboring hepatocytes is a significant concern, and vectors have been developed to increase tumor specificity and decrease off-target toxicity. In this section, we review both DNA and RNA viruses used as oncolytic vectors for liver and biliary cancers and acknowledge current oncolytic clinical trials addressing those tumors in Table 4.

**DNA viruses: adenovirus, herpes viruses, and vaccinia**

The first HCC-specific Ad (CV890) was reported using transcriptional regulatory elements of AFP as replication drivers for Ad5. The vector has E1A and E1B genes under the control of a bicistronic AFP-E1A-IRES-E1B cassette.60 In vivo results demonstrated tumor-volume reduction below baseline 4 weeks after a single viral dose. When combined with doxorubicin, there was synergistic antitumor efficacy, with complete remission after a single instance of combination therapy.60 Using the ONYX015 adenoviral vector
Table 4 Clinical trials with oncolytic viruses for hepatobiliary tumors

<table>
<thead>
<tr>
<th>Vector</th>
<th>Vector details</th>
<th>Phase</th>
<th>Vector intervention</th>
<th>Associated treatment</th>
<th>Trial location</th>
<th>ClinicalTrials. Gov identifier</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaccinia virus</td>
<td>Recombinant Wyeth strain Pexa-Vec (JX594)</td>
<td>III</td>
<td>Three biweekly IT injections</td>
<td>Nivolumab intravenously every 2 weeks Sorafenib twice daily</td>
<td>France</td>
<td>NCT03071094</td>
</tr>
<tr>
<td>Vaccinia virus</td>
<td>Recombinant Wyeth strain Pexa-Vec (JX594)</td>
<td>III</td>
<td>Three biweekly IT injections</td>
<td></td>
<td>Multicentric (98 locations, up to 600 patients)</td>
<td>NCT02562755</td>
</tr>
<tr>
<td>Adenovirus</td>
<td>Telomelysin OBP301</td>
<td>I/II</td>
<td>Dose escalation</td>
<td>None</td>
<td>Korea, Taiwan</td>
<td>NCT02293850</td>
</tr>
<tr>
<td>Adenovirus</td>
<td>Recombinant AdS</td>
<td>III</td>
<td>Followed by TACE</td>
<td>TACE with chemotherapy drugs vs TACE with virus</td>
<td>China</td>
<td>NCT01869088</td>
</tr>
<tr>
<td>Vaccinia</td>
<td>JX594 recombinant vaccinia GM-CSF</td>
<td>II</td>
<td>Five intravenous weekly infusions on days 1, 8, 15, 22, and 29</td>
<td>None</td>
<td>USA, Spain, South Korea</td>
<td>NCT01636284</td>
</tr>
<tr>
<td>Vesicular stomatitis virus</td>
<td>Recombinant vesicular stomatitis virus-expressing IFNβ</td>
<td>I</td>
<td>Single-dose IT injection</td>
<td>None</td>
<td>USA</td>
<td>NCT01628640</td>
</tr>
<tr>
<td>Vaccinia</td>
<td>JX594 recombinant vaccinia GM-CSF</td>
<td>II</td>
<td>Treatments on days 1, 8, 22, week 6, week 12, and week 18</td>
<td>Best supportive care</td>
<td>Multicenter</td>
<td>NCT01387555</td>
</tr>
<tr>
<td>Vaccinia</td>
<td>Thymidine kinase-deleted vaccinia virus plus GM-CSF</td>
<td>II</td>
<td>IT dose on days 1, 15, 29</td>
<td>None</td>
<td>Canada, South Korea, USA</td>
<td>NCT00554372</td>
</tr>
<tr>
<td>Adenovirus</td>
<td>Gene therapy AdS encoding TP53 gene</td>
<td>I</td>
<td>Treatment occurs every 28 days for up to six courses</td>
<td>None</td>
<td>USA</td>
<td>NCT0003147</td>
</tr>
</tbody>
</table>

Abbreviations: Pexa-Vec, pexastimogene devacirepvec; IT, intratumoral; Ad, adenovirus; TACE, transarterial chemoembolization.

A dual-promoter approach has been evaluated as a strategy to enhance tumor specificity and delivery of gene therapy in HCC. A conditionally replicative gene–viral vector system (CNHK500-p53) employed insertion of a TP53 gene-expressing cassette into the viral genome coupled with an hTERT promoter to drive the E1A adenoviral gene and a hypoxia-response-element promoter to drive the adenoviral E1B gene, with the objective of producing p53 protein in hypoxic drive, telomerase-positive HCC cells. In vitro studies demonstrated that p53 expression enhanced viral oncolytic effect. Besides TP53, another tumor suppressor gene, TSLC1, was evaluated using an Ad platform (SD55-TSLC1). In order to increase oncolytic efficacy, another strategy has been to add lethal genes from mitochondria to be expressed by the vector in tumor cells. In 2007, a vector encoding the Smac protein was developed (ZD55-Smac). ZD55-Smac was a superior oncolytic vector but cytotoxicity towards normal cells was a concern.

A number of enhancements to increase safety have been made beyond the initial vector approaches. Tumor-specific promoters have aided with vector selectivity toward tumors in HCC. AFP and transthyretin promoters have been deployed in adenoviral vectors. Similarly, an AFP-regulated ribonucleotide reductase was instituted in a HSV vector, resulting in increased oncolytic effect. A number of promoters have been evaluated in HCC in HSV vectors, which include ANGPTL3, CYP2C8, vitronectin, ADH6, APOB, FBC, ITIH3, and ITIH1. Recently, the promoter for a Golgi protein, GOLPH2 (also called GP73), was successfully instituted as an HCC-specific Ad promoter.

Hybrid promoters are also being used. One such example is HRE-AFP, used in a construct with the bee-venom toxic peptide melittin. Melittin can induce HCC apoptosis, and the vector QG511-HA-melittin exerted an inhibitory effect in HCC and was described as triple-targeting mechanism addressing AFP-positive cells, cells in a hypoxic environment, and cells with p53 deficiency. Furthermore, the use of microRNA (Let7) to control replication was introduced to diminish toxicity. A study utilizing the micro-RNA miR34a for vector specificity allowed for delivery of IL24. Recently, an Ad-expressing lncRNA that can competitively bind oncogenic miRNAs has been shown to achieve promising antitumor efficacy.

A wide range of genes that can elicit oncolytic effects has been evaluated to date. SOCS3 can downregulate cyclin D1...
and antiapoptotic proteins and enhance antitumor effects. Similarly, SOCS1, a negative regulator of STAT3, can inhibit STAT3 phosphorylation and downregulate survivin, cyclin D1, Bcl-xL and C-myc. Another strategy to enhance potency relies on oxygen-dependent degradation domain-regulated vectors that attract NK92 cells into hypoxic tumor microenvironments in animal models. Similarly, a construct using manganese superoxide dismutase (AD55-Mn-SOD) has been shown to suppress HCC growth effectively in xenografted nude mice.

Despite Ad and cisplatin being described as having competitive modes of action, one study has found that cisplatin can be used in combination with Ad. Growth inhibition of HCC by XAF1 in an adenoviral platform (ZD55-XAF1) was pursued in these efforts. XAF1 is a counterregulator of the IAP protein family. With this vector, reduced cisplatin doses were possible and tumor-cell apoptosis enhanced via the activation of the caspase 9–PARP pathway.

Another DNA virus, the vaccinia-based construct JX594, has been shown to be a promising candidate for viroimmunotherapy. Immunostimulation was augmented by GM-CSF transgene expression and evaluated in three patients with hepatitis B-related HCC. In this study, virotherapy was found to induce antivascular cytokines and was associated with tumor vascular shutdown. Interestingly, it also appeared to suppress hepatitis B replication. Correspondingly, another vaccinia strain, GLV1h68, was evaluated in vitro and exhibited cytotoxicity in both sorafenib-sensitive and -resistant HCC cell lines. Preliminary consideration for an immunonominated mechanism of action has been proposed, given observation of tumor response in distant, noninjected tumors in an ongoing clinical study with JX594.

**RNA viruses: vesicular stomatitis virus, measles virus, Newcastle disease virus, and retroviruses**

Vesicular stomatitis virus (VSV) is a negative-strand RNA virus that has been tested in vitro and in vivo immunocompetent mice, with evidence of tumor shrinkage and minimal toxicity. Subsequently, other recombinant forms of VSV, such as rVSV-β-galactosidase, which expresses β-galactosidase to facilitate X-Gal staining of tumors, were tested in HCC. rVSV-β-gal was enabled with tracking capabilities to evaluate multifocal viral spread after arterial delivery of the vector.

Further interest in VSV with chimeric genes to enhance its antitumor effect led to the development of a fusogenic VSV expressing the fusion protein of NDV (rVSV-NDV/F). This new vector was superior to wild-type VSV, with enhanced oncolysis due to syncytia formation and resulted in prolonged survival of rats in vivo. Continued VSV genome engineering yielded improved vector safety using an MA51 deletion in the viral genome. Pursuant to this, the expression of M3, a broad-spectrum and high-affinity chemokine-binding protein from murine γHSV68, enhanced oncolytic potency, resulting in the vector rVSV(MA51)-M3. VSV-hIFNβ was also built around the cornerstone of achieving enhanced safety by using human IFNβ to protect neighboring normal cells from oncolytic damage. This vector is currently undergoing clinical trials.

Other RNA viruses have also been tested in HCC. In 2006, the measles virus Edmonston strain (MV-Edm) entered the scene, due to the establishment of overexpression of CD46 receptors in HCC. CD46 is one of the entry receptors used by MV allowing for cellular entry and syncytia formation. Engineered MV-Edm vectors expressing CEA or human NIS were evaluated in HCC, and demonstrated promising oncolytic potential. MV has also been bioengineered with the suicide gene super-cytosine deaminase, which promotes apoptosis-like death that is not dependent on an intact apoptotic pathway.

NDV is another RNA virus that has been tested in HCC models. An NDV vector harboring an L289A mutation within the F gene resulted in enhanced fusion and cytotoxicity of HCC cells in vitro compared to an rNDV/F3aa control virus. Experiments with RNA retroviruses have demonstrated oncolytic effect in HCC. Vectors derived from the murine leukemia virus-based replicating retrovirus vector (RRV) and GALV have been evaluated in HCC. GALV RRV-mediated suicide gene therapy efficiently suppressed HCC tumor growth in vivo, and no detectable RRV signals were observed outside the tumor.

Cholangiocarcinoma receptors have exhibited a wider level of heterogeneity with regard to receptors for viral entry. One study addressed this issue by modifying the vector with ligands that would better enable integrin-dependent infection. An RGD-fiber modification was used to improve the infectivity and subsequent efficacy of adenoviral vectors in biliary cancers. Biliary cancers remain somewhat understudied with regard to OV. Additional studies are needed in this regard to better inform OV approaches in biliary cancers.

**Future directions**

Despite the continuous evolution of vectors, particularly at the genomic level, and the increasing tumor specificity achieved, it is clear that the overall efficacy of OV therapy needs to be improved. One aspect of significant concern is
the delivery method, which needs to be designed in a way to enhance viral bioavailability and viral dissemination throughout the tumor. An excellent delivery method would provide a shield to immunoneutralization and would also increase virus bystander-killing potency by enhancing tumor-cell infection. Another approach to improve oncolytic efficacy is to enhance the replication capacity of tumor-selective viral strains to achieve better tumor penetration. The challenges observed to date show that the more bioengineering modifications a virus is subjected to, the less potent it becomes in relation to its wild type. There is no genomic manipulation thus far that has been able to increase potency. As such, after safety and tumor specificity have been developed, it is about time for future work to show an increase in killing power of safe vectors.

**Conclusion**

Oncolytic vectors are very diverse, and their development has evolved to establish tumor selectivity and safety. For cancers with dismal OS rates, virotherapy represents a promising therapeutic platform for further evaluation. A broader array of clinical studies evaluating OV is anticipated in the years to come. In particular, combinations of virotherapies with immunotherapies, such as immunoncheckpoint inhibitors and standard cytotoxic chemotherapies, will be of particular interest. More tailored, precision-medicine-informed approaches will likely also constitute an area of future exploration. A number of challenges are yet to be addressed to allow for the realization of the full potential of OV. These include drug delivery of vectors to tumors with sequestration in normal tissues/organisms, ability to overcome/avoid host immunoresponse to allow for repeated dosing, and ability to enable systemic administration of vectors to permit broader adaptation of these therapies. The framework to address these challenges and explore the myriad available opportunities has been laid, and as such, a brave new era awaits this burgeoning field.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


